Frédéric Lehmann

Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor

Hideyuki Ikeda, Bernard Lethé, Frédéric Lehmann et al. · Immunity · 1997 · 765 citations · Full text

Tumor Immunology, Cancer Immunosurveillance, Nk Inhibitory Receptor +8

Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy

Fernando Ulloa‐Montoya, Jamila Louahed, Benjamin Dizier et al. · Journal of Clinical Oncology · 2013 · 461 citations · Full text

Pretreatment Expression, Immunology, Immunoediting +20

A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Pierre G. Coulie, Frédéric Lehmann, Bernard Lethé et al. · Proceedings of the National Academy of Sciences · 1995 · 419 citations · Full text

Cancer Immunosurveillance, Human Melanoma, Medicine +14

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma

Susanne H.C. Baumeister, Joana Murad, Lillian Werner et al. · Cancer Immunology Research · 2018 · 317 citations · Full text

Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results

Johan Vansteenkiste, M. Zieliński, A. Linder et al. · Journal of Clinical Oncology · 2013 · 312 citations · Full text